Germany's Eckert & Ziegler Q1 sales rise on medical segment growth

Eckert & Ziegler SE

12/05/2026 06:52

Overview

Germany isotope specialist's Q1 sales rose 7% yr/yr, net income up 7%

Adjusted EBIT for Q1 fell 2% due to weaker product mix in Isotope Products

Company confirmed 2026 sales and EBIT forecast

Outlook

Eckert & Ziegler confirms 2026 sales forecast of around €320 mln

Company maintains 2026 adjusted EBIT forecast at around €80 mln

Result Drivers

MEDICAL SEGMENT GROWTH - Higher sales in Medical segment, driven by pharmaceutical radioisotopes, generators, and CDMO services

ISOTOPE PRODUCTS WEAKNESS - Weaker product mix in Isotope Products segment led to lower adjusted EBIT and sales decline early in quarter

Company press release: ID:nEQ8GWzbpa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
EUR 72.90 mln
Q1 EPS
EUR 0.17
Q1 Net Income
EUR 10.40 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Eckert & Ziegler SE is €21.00, about 36.1% above its May 11 closing price of €15.43

The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 18 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)